Amgen Inc. (AMGN) Social Stream



Amgen Inc. (AMGN): $251.30

1.95 (+0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

Featured Post From StockTwits About AMGN

Hi JusTrading followers. Closing Bell video (4/28/2021) for Thursday (4/29/2021). Are you holding ETFs or Stocks? check out our video and get more information about: possible buy and sell prices, expected returns, charts and more.
https://www.youtube.com/watch?v=CjcbCsvCctk
SUGGESTED STOCKS
Bearish Energy Stock: Marathon Petroleum ($MPC): 00:04:44
Bullish Healthcare Stock: Amgen Incorporated ($AMGN): 00:11:45
justradingUS, published April 29, 2021

What Else are AMGN Traders Talking About?


Other tickers frequently mentioned alongside AMGN are ATNF, JNJ, ABBV and NVS.

Other Notable StockTweets About AMGN


$ATNF 👉🏻 The founders have significant expertise in developing new therapeutics that were sold to big pharma for billions. They are renowned for development of some of the largest-selling drugs to ever come to market. Now they aim to do it again with a pipeline of drug candidates in sequential stages of development that address large untapped markets. The founding scientists at 180 Life Sciences discovered the anti-TNF drug class that led to Remicade, the fourth all-time best-selling drug in the world. Presently owned by $JNJ , Remicade has exceeded $90 billion in total sales since approval. $ABBV licensed the anti-TNF patents from these scientists for use with Humira, the second best-selling drug in the world, with lifetime sales of $137 billion. $AMGN licensed the seventh best seller, Enbrel, that treats psoriasis and rheumatoid arthritis and has generated over $81 billion lifetime sales. $NVS licensed the world’s 12th best-selling drug, Diovan, has over $60 billion in sales.

MDInvestments, published April 23, 2021

$ATNF 👉🏻 The founders have significant expertise in developing new therapeutics that were sold to big pharma for billions. They are renowned for development of some of the largest-selling drugs to ever come to market. Now they aim to do it again with a pipeline of drug candidates in sequential stages of development that address large untapped markets. The founding scientists at 180 Life Sciences discovered the anti-TNF drug class that led to Remicade, the fourth all-time best-selling drug in the world. Presently owned by $JNJ , Remicade has exceeded $90 billion in total sales since approval. $ABBV licensed the anti-TNF patents from these scientists for use with Humira, the second best-selling drug in the world, with lifetime sales of $137 billion. $AMGN licensed the seventh best seller, Enbrel, that treats psoriasis and rheumatoid arthritis and has generated over $81 billion lifetime sales. $NVS licensed the world’s 12th best-selling drug, Diovan, has over $60 billion in sales.

MDInvestments, published April 15, 2021

$ATNF in addition to Huge Short Squeeze incoming (today if we add a few more buyers).. ATNF has best management in bio:
ATNF Management Team
Dr James Woody: Discovered Remicade ( $JNJ acquired for $5 Billion. Sales of $50B+ since approval). Founded Avidia & Proteolix (sold to $AMGN ). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Sir Marc Feldman: Emeritus at Oxford. Discovered anti-TNF Biologics (ie Remicade, Humira etc) $150B class by 2025. Lead clinical trial for drug Remicade (J&J acquired for $5B). Lasker award winner (2nd only to Nobel).

Prof Raphael Mechoulam: Discovered the body’s endocannabinoid system. Harvey Award 2020 winner for Synthetic THC CBD analogs. (Potential 2021 Nobel nominee).

Prof Lawrence Steinman: chair of Neurology Dept at Stanford. Founder of Neurocrine Bio (now $9B) discovered role of integrins, and Tysabri to treat MS ( $BIIB acquired for $3B).

Dr Jonathan Rothbard: Stanford. Founder of Amylin (sold to $BMY for $5 Billion).

SCNC, published April 9, 2021

1,495 days since R/S butchery + #MismanagementMike #Castagnant = pathetic 0.818 cents. Delayed pediatric approval + ultra rapid acting label overdue + CEO rejected deals for international Technosphere expansion = until a $MNKD buyout or #HostileTakeover we stay in single digit purgatory. F*ck U Mike. #ReadySetInhale #PatientsDeserveAccess #MediocreMike #MoronMike🖕🏻#NewLeadershipNow #PfefferSucks #Bourla4BOD $PFE #Hooper4CEO $AMGN #GeoffMartha4BOD $MDT #Rothblatt4BOD #Joergensen4BOD #ReJoyce4BOD #SayerTheSavior4BOD $DXCM #Bradway4BOD #SendHelpMyCEOBlows #GreedyCEgO #CEOsabotage #CEOsuffocation #BotchedUAE #TechnosphereSquandered #PaltryPlus26k #RetirementUnfux0red #TrueLongs #PreReverseSplit

trondisc, published April 5, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7191 seconds.